The Use of HOVR Technology for Assessment of Blood Associated Parameters

Diabetes Mellitus Clinical Trial

Official title:

The Use of Hemodynamic Occlusive and Vascular Response (HOVR) Technology for the Measurement of Absorption of Light in Order to Derive Changes of Perfusion and Oxygen Levels in the Foot.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05921461
• Other study ID #: PedCheck-V1-2.1
• Status: Completed
• Start date: May 1, 2022
• Est. completion date: March 16, 2023

Study information

• Verified date: June 2023
• Source: Votis Subdermal Imaging Technologies LTD
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Feasibility, usability and safety clinical study that is aimed at testing of the non-invasive VOTIS PedCheck system for measurement of changes in absorption of light in order to derive changes in perfusion and oxygen levels in the foot.

Description:

Introduction: Peripheral Arterial Disease (PAD) affects 8-12 million people in the United States, and approximately 230 million worldwide. When linked with diabetes, PAD results in over 71,000 amputations annually. Patients with PAD have decreased lower extremity arterial perfusion which is commonly referred to as "poor circulation." In most cases of PAD, atherosclerotic plaques narrow the arterial flow lumen which restricts blood flow to the distal extremity. This condition is characterized by progressive vessel obstructions, associated with cardiovascular (CV) events, including myocardial infarction (MI), stroke, limb ischemia, and CV death. Although PAD is a prevalent condition, it is still considered as an underdiagnosed manifestation of atherosclerosis. PAD is one of the most common vascular complications of diabetes, and can cause foot ischemia which is associated with non healing wounds, gangrene and amputations. At present there is no gold standard or test/device to identify, evaluate, and monitor the circulatory health of the foot in a reliable and precise way. In addition, calcification of blood vessels in patients with diabetes complicates the evaluation of perfusion in the foot. Since diabetes has reached epidemic proportions (60M people affected in Europe), there is an urgent need for additional measurement tools for assistance for the evaluation of PAD complications. The current study is aimed at feasibility, usability and safety testing of the non-invasive VOTIS PedCheck system as an assessment tool of PAD. The protocol allows for 30 PAD patients and 30 self assessed healthy controls. Objectives: - To assess the safety of the PedCheck device using HOVR technology - To calibrate the measurement of changes in absorption of light in order to derive relative perfusion and oxygen levels in the foot. - To compare between PAD and non-PAD populations using HOVR. Secondary objective: • To collect data regarding the usability of the PedCheck device. Description of investigational product: Votis PedCheck portable device comprises patches affixed to the foot with encased laser diodes and photodetector sensors that automatically measure absorption of the light. Via lightweight leads, the patches link to a central control and display device. In addition an inflatable blood pressure cuff is placed above the knee. The control device sets the inflation and deflation of the cuff according to the protocol.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: March 16, 2023
• Est. primary completion date: March 16, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Men and Women
• Age >40
• Subject must be willing and able to sign an Informed Consent form to participate in the clinical study.

Exclusion Criteria:

• Pregnant and breastfeeding woman
• Any severe concurrent disease which in the judgment of the investigator would make the subject inappropriate for the purposes of this study.

Control group Inclusion Criteria:

• Good health according to self-report

Control group exclusion Criteria:

• History of diabetes and/or a cardiovascular disease according to self-report
• History of heavy smoking (20 cigarettes a day) for at least one year during the last 5 years prior to consent
• Family history of severe cardiovascular disease, i.e. sudden cardiac death below the age of 50, according to self-report
• Use of anti-hypertension drugs

PAD group Inclusion Criteria:

• Subjects who are suspected of having PAD and have undergone or are planned to undergo ABI testing within 60 days prior to or after ICF signature

PAD group exclusion Criteria:

• Existence of a WIfI graded severe foot infection (Infection grade 3) or severe infection (Infection grade 4), i.e. local infection or general infection with signs of systemic inflammatory response syndrome.
• Amputation or a surgical procedure on the foot during the last 2 weeks

Related Conditions & MeSH terms

• Diabetes Mellitus
• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Locations

Country	Name	City	State
Israel	Hadassah University Medical Center	Jerusalem

Sponsors (2)

Lead Sponsor	Collaborator
Votis Subdermal Imaging Technologies LTD	Hadassah Medical Organization

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severe adverse device effects or serious adverse events that are recorded using standard adverse event report forms	Observation of adverse skin changes or tissue damage or reports of discomfort.	Through study completion, an average of 1 year.
Primary	PedCheck parameters that demonstrate correlation between HOVR and Ankle Brachial Index (ABI) and Toe Brachial Index (TBI).	HOVR score 0-100. 0-40 being no PAD, 40-100 being increasingly severe PAD.	Through study completion, an average of 1 year.
Secondary	Evaluation of usability based on collected data using standard convenience scoring questionnaires.	Usability will be evaluated by standard usability patient and operator questionnaires for scoring convenience. Convenience will be rated by numerical rating scale for scoring convenience 0-5 where 0 represents very hard and 5 very easy.	Through study completion, an average of 1 year.
Secondary	Evaluation of usability based on collected data using standard pain scoring questionnaires.	Usability will be evaluated by Numerical rating scale for scoring pain. 0-10 where 0 represents no pain and 10 the most severe.	Through study completion, an average of 1 year.